JP2007506084A - ナノ粒子コンジュゲート及びその製造方法 - Google Patents
ナノ粒子コンジュゲート及びその製造方法 Download PDFInfo
- Publication number
- JP2007506084A JP2007506084A JP2006526693A JP2006526693A JP2007506084A JP 2007506084 A JP2007506084 A JP 2007506084A JP 2006526693 A JP2006526693 A JP 2006526693A JP 2006526693 A JP2006526693 A JP 2006526693A JP 2007506084 A JP2007506084 A JP 2007506084A
- Authority
- JP
- Japan
- Prior art keywords
- nanoparticles
- peptide
- nanoparticle
- nanoparticle conjugate
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 389
- 238000004519 manufacturing process Methods 0.000 title claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 212
- 239000003446 ligand Substances 0.000 claims abstract description 89
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 69
- 238000000034 method Methods 0.000 claims abstract description 16
- 235000018417 cysteine Nutrition 0.000 claims abstract description 15
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 7
- 239000010931 gold Substances 0.000 claims description 42
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 28
- 230000015572 biosynthetic process Effects 0.000 claims description 28
- 229910052737 gold Inorganic materials 0.000 claims description 27
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 23
- 125000000524 functional group Chemical group 0.000 claims description 22
- 238000003786 synthesis reaction Methods 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 229960002685 biotin Drugs 0.000 claims description 14
- 235000020958 biotin Nutrition 0.000 claims description 14
- 239000011616 biotin Substances 0.000 claims description 14
- 125000000539 amino acid group Chemical group 0.000 claims description 13
- 150000003573 thiols Chemical class 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 108010090804 Streptavidin Proteins 0.000 claims description 9
- 238000009739 binding Methods 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090001008 Avidin Proteins 0.000 claims description 8
- 238000003556 assay Methods 0.000 claims description 8
- 230000027455 binding Effects 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 8
- 239000002953 phosphate buffered saline Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 235000018102 proteins Nutrition 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- 235000000346 sugar Nutrition 0.000 claims description 7
- 230000004001 molecular interaction Effects 0.000 claims description 6
- -1 salt compound Chemical class 0.000 claims description 6
- 239000004065 semiconductor Substances 0.000 claims description 6
- 229910052709 silver Inorganic materials 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 5
- 238000013537 high throughput screening Methods 0.000 claims description 5
- 230000003287 optical effect Effects 0.000 claims description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- 229910017052 cobalt Inorganic materials 0.000 claims description 4
- 239000010941 cobalt Substances 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 238000007901 in situ hybridization Methods 0.000 claims description 4
- 238000011534 incubation Methods 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 239000004332 silver Substances 0.000 claims description 4
- 150000008163 sugars Chemical class 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 3
- 238000004458 analytical method Methods 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 3
- 230000001808 coupling effect Effects 0.000 claims description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000003792 electrolyte Substances 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 239000000696 magnetic material Substances 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 239000005083 Zinc sulfide Substances 0.000 claims description 2
- UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical compound [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 claims description 2
- 230000002559 cytogenic effect Effects 0.000 claims description 2
- 238000000684 flow cytometry Methods 0.000 claims description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 238000003364 immunohistochemistry Methods 0.000 claims description 2
- 239000007769 metal material Substances 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 238000001742 protein purification Methods 0.000 claims description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 2
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 229910052984 zinc sulfide Inorganic materials 0.000 claims description 2
- DRDVZXDWVBGGMH-UHFFFAOYSA-N zinc;sulfide Chemical compound [S-2].[Zn+2] DRDVZXDWVBGGMH-UHFFFAOYSA-N 0.000 claims description 2
- 238000002509 fluorescent in situ hybridization Methods 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 66
- 239000002245 particle Substances 0.000 description 56
- 239000011780 sodium chloride Substances 0.000 description 33
- 238000002474 experimental method Methods 0.000 description 30
- 230000002776 aggregation Effects 0.000 description 25
- 238000004220 aggregation Methods 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 21
- 229940024606 amino acid Drugs 0.000 description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 19
- 150000001413 amino acids Chemical class 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 230000003993 interaction Effects 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 15
- 239000012071 phase Substances 0.000 description 14
- 230000007774 longterm Effects 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 230000006641 stabilisation Effects 0.000 description 12
- 238000011105 stabilization Methods 0.000 description 12
- 230000002209 hydrophobic effect Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 229920002971 Heparan sulfate Polymers 0.000 description 9
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 239000002082 metal nanoparticle Substances 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000008878 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 238000001209 resonance light scattering Methods 0.000 description 6
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 235000009582 asparagine Nutrition 0.000 description 5
- 229960001230 asparagine Drugs 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000006471 dimerization reaction Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 239000002122 magnetic nanoparticle Substances 0.000 description 4
- 150000002730 mercury Chemical class 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 239000013545 self-assembled monolayer Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- DYAOREPNYXXCOA-UHFFFAOYSA-N 2-sulfanylundecanoic acid Chemical compound CCCCCCCCCC(S)C(O)=O DYAOREPNYXXCOA-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 3
- 241000238366 Cephalopoda Species 0.000 description 3
- 229920002271 DEAE-Sepharose Polymers 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229910001961 silver nitrate Inorganic materials 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 108700005102 CALNN peptide Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 238000003917 TEM image Methods 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000003340 combinatorial analysis Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- 230000002380 cytological effect Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000000598 lipoate effect Effects 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 230000005415 magnetization Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000011368 organic material Substances 0.000 description 2
- 239000003444 phase transfer catalyst Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000002109 single walled nanotube Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 description 1
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical compound SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010007337 Azurin Proteins 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- 108091016585 CD44 antigen Proteins 0.000 description 1
- 229910021503 Cobalt(II) hydroxide Inorganic materials 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- 101000597662 Homo sapiens Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform Proteins 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100035348 Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform Human genes 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 150000001356 alkyl thiols Chemical class 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012237 artificial material Substances 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 150000001868 cobalt Chemical class 0.000 description 1
- ASKVAEGIVYSGNY-UHFFFAOYSA-L cobalt(ii) hydroxide Chemical compound [OH-].[OH-].[Co+2] ASKVAEGIVYSGNY-UHFFFAOYSA-L 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229940117389 dichlorobenzene Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- ZBKIUFWVEIBQRT-UHFFFAOYSA-N gold(1+) Chemical compound [Au+] ZBKIUFWVEIBQRT-UHFFFAOYSA-N 0.000 description 1
- OIZJPMOIAMYNJL-UHFFFAOYSA-H gold(3+);trisulfate Chemical compound [Au+3].[Au+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O OIZJPMOIAMYNJL-UHFFFAOYSA-H 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 108010083213 heparitinsulfate lyase Proteins 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 150000003141 primary amines Chemical group 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 239000002094 self assembled monolayer Substances 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
- QBVXKDJEZKEASM-UHFFFAOYSA-M tetraoctylammonium bromide Chemical compound [Br-].CCCCCCCC[N+](CCCCCCCC)(CCCCCCCC)CCCCCCCC QBVXKDJEZKEASM-UHFFFAOYSA-M 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/588—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with semiconductor nanocrystal label, e.g. quantum dots
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Nanotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0321937.5A GB0321937D0 (en) | 2003-09-19 | 2003-09-19 | Nanoparticle conjugates and method of production thereof |
| PCT/GB2004/003986 WO2005029076A2 (en) | 2003-09-19 | 2004-09-20 | Nanoparticle conjugates and method of production thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007506084A true JP2007506084A (ja) | 2007-03-15 |
| JP2007506084A5 JP2007506084A5 (enExample) | 2007-10-25 |
Family
ID=29266267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006526693A Pending JP2007506084A (ja) | 2003-09-19 | 2004-09-20 | ナノ粒子コンジュゲート及びその製造方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070054337A1 (enExample) |
| EP (1) | EP1664776A2 (enExample) |
| JP (1) | JP2007506084A (enExample) |
| AU (1) | AU2004274694A1 (enExample) |
| CA (1) | CA2539501A1 (enExample) |
| GB (1) | GB0321937D0 (enExample) |
| WO (1) | WO2005029076A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009529004A (ja) * | 2006-02-27 | 2009-08-13 | インダストリー−アカデミック コーポレーション ファウンデーション，ヨンセイ ユニバーシティ | 相転移リガンドでコートされた水溶性磁性または水溶性金属酸化物ナノ粒子とその製造方法及び用途 |
| JP2015521198A (ja) * | 2012-05-29 | 2015-07-27 | ザ ユニバーシティ オブ バーミンガム | 付着したｄｎａ修復阻害剤及び核局在化シグナル要素を含むナノパーティクル |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9434770B2 (en) * | 2004-10-07 | 2016-09-06 | Tapas K Das Gupta | Modified cupredoxin derived peptides |
| JP5059312B2 (ja) * | 2005-09-16 | 2012-10-24 | Ｈｏｙａ株式会社 | 高分散性リン酸カルシウム系化合物ナノ粒子及びその製造方法 |
| KR20090059148A (ko) | 2006-09-11 | 2009-06-10 | 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 | 쿠프레독신 유래된 펩티드의 변형 및 이의 이용 방법 |
| JP5746469B2 (ja) | 2006-10-04 | 2015-07-08 | ブルックヘブン サイエンス アソシエイツ | Ｄｎａによって導かれたナノ粒子凝集 |
| WO2008134586A1 (en) * | 2007-04-27 | 2008-11-06 | The Regents Of The University Of California | Site-specific conjugation of ligands to nanoparticles |
| WO2009002837A1 (en) * | 2007-06-26 | 2008-12-31 | Massachusetts Institute Of Technology | Controlled modification of semiconductor nanocrystals |
| CN101113457B (zh) * | 2007-07-04 | 2010-05-19 | 中国科学院长春应用化学研究所 | 富精氨酸寡肽-金纳米粒子细胞传输载体合成方法 |
| EP2240782A2 (en) * | 2008-02-04 | 2010-10-20 | Ulive Enterprises Limited | Nanoparticle conjugates |
| US8729012B2 (en) * | 2008-06-02 | 2014-05-20 | Brookhaven Science Associates, Llc | Controllable assembly and disassembly of nanoparticle systems via protein and DNA agents |
| KR101014246B1 (ko) * | 2008-07-03 | 2011-02-16 | 포항공과대학교 산학협력단 | 페하 민감성 금속 나노 입자 및 이의 제조 방법. |
| US20100261185A1 (en) | 2009-03-27 | 2010-10-14 | Life Technologies Corporation | Labeled enzyme compositions, methods and systems |
| WO2011011631A2 (en) * | 2009-07-22 | 2011-01-27 | Samuel Zalipsky | Nucleic acid delivery vehicles |
| WO2011031478A1 (en) * | 2009-08-27 | 2011-03-17 | Brown University | Fe3o4-m(au-like)-nanoparticles for antibody-conserving target-specific platin delivery |
| US8378075B2 (en) * | 2009-10-27 | 2013-02-19 | The United States Of America, As Represented By The Secretary Of The Navy | Covalent attachment of peptides and biological molecules to luminescent semiconductor nanocrystals |
| US9114107B2 (en) | 2010-10-05 | 2015-08-25 | Drexel University | Compositions for inhibiting virus entry and promoting virolysis, and methods thereof |
| US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| DK3489685T3 (da) | 2011-11-21 | 2023-12-04 | Zoetis Services Llc | Signalforstærkning i sidestrømning og tilsvarende immunoassays |
| US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
| US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| CN102896325B (zh) * | 2012-10-12 | 2014-04-16 | 江南大学 | 一种基于无机小分子盐的金纳米棒手性自组装材料制备方法 |
| CN103058133B (zh) * | 2013-01-30 | 2014-01-08 | 江南大学 | 一种基于非手性小分子组装手性纳米材料的制备方法 |
| US9234078B2 (en) | 2013-03-21 | 2016-01-12 | The Regents Of The University Of Michigan | Conjugated gold nanoparticles |
| US9233138B2 (en) | 2013-10-22 | 2016-01-12 | Drexel University | Compositions for promoting HIV-1 virolysis and methods using same |
| SG10201912301XA (en) | 2013-11-04 | 2020-02-27 | Uti Lp | Methods and compositions for sustained immunotherapy |
| TWI691716B (zh) | 2014-08-13 | 2020-04-21 | 美商艾巴希斯公司 | 電漿特異性結合搭配物檢定中之信號放大 |
| US12011480B2 (en) | 2015-05-06 | 2024-06-18 | Uti Limited Partnership | Nanoparticle compositions for sustained therapy |
| JP6944438B2 (ja) | 2015-08-04 | 2021-10-06 | ゾエティス サービシズ リミテッド ライアビリティ カンパニー | 溶液ベースのプラズモン特異的結合パートナーアッセイにおけるシグナル増幅 |
| WO2018094213A1 (en) * | 2016-11-18 | 2018-05-24 | Kansas State University Research Foundation | Microfluidics-based nanobiosensors and devices |
| KR102654470B1 (ko) | 2017-01-30 | 2024-04-05 | 조에티스 서비시즈 엘엘씨 | 용액-기반 플라스몬 특이적-결합 파트너 검정 및 금속성 나노구조체 |
| CN111741746A (zh) | 2017-11-29 | 2020-10-02 | 乌第有限合伙公司 | 治疗自身免疫性疾病的方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6086881A (en) * | 1998-05-15 | 2000-07-11 | Children's Medical Center Corp. | Spatially aligned conjugated composition having a thioether bond linkage |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6121425A (en) * | 1994-07-29 | 2000-09-19 | Nanoprobes, Inc. | Metal-lipid molecules |
| US6368877B1 (en) * | 1997-06-25 | 2002-04-09 | Massachusetts Institute Of Technology | Self-assembling peptide surfaces for cell patterning and interactions |
| US6953656B2 (en) * | 2000-07-14 | 2005-10-11 | Massachusetts Institute Of Technology | Direct, externally imposed control of polypeptides |
-
2003
- 2003-09-19 GB GBGB0321937.5A patent/GB0321937D0/en not_active Ceased
-
2004
- 2004-09-20 EP EP04768532A patent/EP1664776A2/en not_active Withdrawn
- 2004-09-20 AU AU2004274694A patent/AU2004274694A1/en not_active Abandoned
- 2004-09-20 US US10/572,435 patent/US20070054337A1/en not_active Abandoned
- 2004-09-20 WO PCT/GB2004/003986 patent/WO2005029076A2/en not_active Ceased
- 2004-09-20 CA CA002539501A patent/CA2539501A1/en not_active Abandoned
- 2004-09-20 JP JP2006526693A patent/JP2007506084A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6086881A (en) * | 1998-05-15 | 2000-07-11 | Children's Medical Center Corp. | Spatially aligned conjugated composition having a thioether bond linkage |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009529004A (ja) * | 2006-02-27 | 2009-08-13 | インダストリー−アカデミック コーポレーション ファウンデーション，ヨンセイ ユニバーシティ | 相転移リガンドでコートされた水溶性磁性または水溶性金属酸化物ナノ粒子とその製造方法及び用途 |
| JP2015521198A (ja) * | 2012-05-29 | 2015-07-27 | ザ ユニバーシティ オブ バーミンガム | 付着したｄｎａ修復阻害剤及び核局在化シグナル要素を含むナノパーティクル |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004274694A1 (en) | 2005-03-31 |
| US20070054337A1 (en) | 2007-03-08 |
| CA2539501A1 (en) | 2005-03-31 |
| GB0321937D0 (en) | 2003-10-22 |
| WO2005029076A2 (en) | 2005-03-31 |
| EP1664776A2 (en) | 2006-06-07 |
| WO2005029076A3 (en) | 2005-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007506084A (ja) | ナノ粒子コンジュゲート及びその製造方法 | |
| CN102066941B (zh) | 用于生物传感器的新型Au/Ag核-壳复合材料 | |
| US20110165647A1 (en) | Nanoparticle conjugates | |
| US7253277B2 (en) | Nanoparticle polyanion conjugates and methods of use thereof in detecting analytes | |
| CN102559170B (zh) | 一种鲁米诺发光功能化的纳米银及其制备方法和应用 | |
| US20120202218A1 (en) | Detection method and device based on nanoparticle aggregation | |
| CN104316698A (zh) | 固定有抗原的免疫荧光载片的制备方法和由该方法制备的免疫荧光载片 | |
| JP2011505580A (ja) | バイオプローブと、その製造方法、それを利用した分析装置及び分析方法 | |
| Wang et al. | Epitope imprinted polymer nanoparticles containing fluorescent quantum dots for specific recognition of human serum albumin | |
| Yang et al. | A novel platform for high sensitivity determination of PbP2a based on gold nanoparticles composited graphitized mesoporous carbon and doxorubicin loaded hollow gold nanospheres | |
| JP2006508095A (ja) | 粒子の生物活性化 | |
| KR20040083095A (ko) | 페라이트 결합 유기 물질 및 이의 제조 방법 | |
| Qiao et al. | Antibody and DNA dual-labeled gold nanoparticles: Stability and reactivity | |
| Woolley et al. | From particle to platelet: optimization of a stable, high brightness fluorescent nanoparticle based cell detection platform | |
| Cháfer-Pericás et al. | Functionalized inorganic nanoparticles used as labels in solid-phase immunoassays | |
| JP4335526B2 (ja) | コロイド構造体および非コロイド構造体による結合スピーシーズの検出 | |
| US20180003709A1 (en) | Heterodimeric core-shell nanoparticle in which raman-active molecules are located at a binding portion of a nanoparticle heterodimer, use thereof, and method for preparing same | |
| Powell et al. | Giant platinum clusters: 2-nm covalent metal cluster labels | |
| Hainfeld et al. | Nanoparticle molecular labels | |
| JP2010002393A (ja) | 標的物質の検出方法 | |
| Brayner | Current Approaches in Natural BiopolymerNanoparticle Hybrid Functional Materials: From Drug Delivery to Bio-Detection Applications | |
| Elbayomy | Modification and Application of Gold Nanorods in Surface Enhanced Raman Scattering Based Assays | |
| Liu | Developing Novel Interface and Signal Amplification Strategies for Study of Biological Interactions by Surface Plasmon Resonance (SPR) and SPRimaing | |
| HK1158309B (en) | Novel au / ag core-shell composite useful for biosensor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070905 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070905 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091118 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100414 |